Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 139   

Articles published

NVS 93.90 -0.90 (-0.95%)
price chart
Watch List Highlights - Apple Inc. (NASDAQ:AAPL), Novartis AG (ADR) (NYSE ...
Novartis AG (ADR) (NYSE:NVS) Basel disclosed Friday analyses that confirm the high efficacy of the NVS drug Gilenya (fingolimod) in achieving 'no evidence of disease activity' in patients with relapsing-remitting multiple sclerosis.
Battle Between Roche's Avastin And Novartis' Lucentis Heats Up
The study say that this renders the practice by health regulatory bodies of favoring Novartis AG (ADR)'s (NVS) costlier drug Lucentis as pointless and unnecessary.
Related articles »  
Novartis Wins The Battle Over Bronchodilators Against GSK
Novartis AG ADR (NVS) reported yesterday that its once-daily Ultibro (Breezhaler) bronchodilator outperformed GlaxoSmithKline plc's (ADR) (GSK) twice-daily blockbuster Seretide (Accuhaler) bronchodilator in Phase-III trials.
Related articles »  
Pharma Boom: 14 Biosimilars To Debut In The US
Novartis AG (ADR) (NVS) was the first company to file for an. The company wants to sell a biosimilar to Amgen, Inc.'s (AMGN) biotech cancer drug Neupogen, which brought in sales of $1.4 billion last year.
Related articles »  
Novartis Stock Reaches 3-Year High On Successful Heart Failure Drug Trials
Novartis AG ADR (NVS) stock rose 4.3% and closed at 85.9 Swiss francs yesterday on the Zurich Exchange. This was the stock's biggest gain since September 2011, driven by successful Phase III trials conducted on Novartis' experimental heart failure drug ...
Related articles »  
Pharma Stocks To Watch This Week
Novartis AG (ADR) (NVS) has already presented in the conference, taking GSK head-on with positive Phase III results for its Ultibro Breezhaler.
Pfizer Signs Agreement To Market Novartis' Respiratory Inhalers In UK
Pfizer Inc. (PFE) has entered into an agreement with Novartis AG (ADR) (NVS), under which Pfizer's UK-based business, officially named Pfizer Limited, will be responsible for the commercialization of Novartis' two respiratory inhalers, Seebri ...
Related articles »  
Unbeatable Move at Healthcare Sector- Novartis AG (ADR) (NYSE:NVS), Eli Lilly ...
Swiss pharma giant Novartis AG (ADR) (NYSE:NVS) [Trend Analysis] was up around 4 percent to a new far above the ground following it released positive clinical-trial data on its heart-failure drug in excess of the weekend.
Related articles »  
Novartis's Generics Unit May Benefit From Biomedicine Patent Expiry
Switzerland-based Novartis AG's (NVS) generic unit goes by the name of Sandoz, and it is the number one player in biosimilars.
Related articles »  
Amgen Presents Positive Trial Results For Heart Drug Ivabradine
Amgen, Inc. (AMGN) presented positive Phase III trial results yesterday, for its heart failure drug ivabradine at the Heart Failure Society of America's (HFSA) 18th Annual Scientific Meeting being held in Las Vegas.
Related articles »